arna-ex991_7.pptx.htm
Etrasimod in Ulcerative Colitis: Promising Phase 2 Results - Gastroenterology Advisor
Frontiers | Frontiers in Drug Research and Development for Inflammatory Bowel Disease | Pharmacology
arna-10k_20181231.htm
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Col
Innovations in Oral Therapies for Inflammatory Bowel Disease | Semantic Scholar
Next generation of small molecules in inflammatory bowel disease | Gut
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis - Gastroenterology
S1P mechanisms of action. This figure was made with Servier Medical Art... | Download Scientific Diagram
New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound - Gastroenterology
Results from ADVISE: a randomized, double-blind, placebo-controlled phase 2 study of etrasimod, an oral, selective, sphingosine
Frontiers | Frontiers in Drug Research and Development for Inflammatory Bowel Disease | Pharmacology
Mongersen, tofacitinib, filgotinib: mechanisms of action. The... | Download Scientific Diagram
Arena Pharmaceuticals Inc (ARNA)
PDF) Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery
Mechanism of action of sphingosine receptor modulators. Ozanimod is an... | Download Scientific Diagram
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects | SpringerLink
Mongersen, tofacitinib, filgotinib: mechanisms of action. The... | Download Scientific Diagram
The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental
Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells
Novel Targeted Therapies for Inflammatory Bowel Disease: Trends in Pharmacological Sciences
etrasimod | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
My 2 Cents On The Ozanimod Saga (NASDAQ:CELG) | Seeking Alpha
Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases: Trends in Molecular Medicine
